Vimarsana
Biggest News Aggregation in the World

Page 7 - Toby Maher News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Toby Maher. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Toby Maher Today - Breaking & Trending Today

Vicore Pharma Holding AB: Vicore announces multiple scientific abstracts and presentations at upcoming conferences during the autumn - Vimarsana News

Vicore Pharma Holding AB: Vicore announces multiple scientific abstracts and presentations at upcoming conferences during the autumn

GOTHENBURG, Sweden, Aug. 19, 2022 /PRNewswire/ -- Vicore Pharma Holding AB (publ) ("Vicore"), a clinical-stage pharmaceutical company developing medicines targeting the angiotensin II type 2

Vicore Pharma Holding AB: Vicore IPF interim data selected as an oral late-breaker at the ERS congress - Vimarsana News

Vicore Pharma Holding AB: Vicore IPF interim data selected as an oral late-breaker at the ERS congress

The AIR trial is a single arm, multicenter phase 2 study in patients with idiopathic pulmonary fibrosis (IPF)Interim data have shown stabilization of the disease and an increase in lung capacity

Vicore IPF interim data selected as an oral "late-breaker" at the ERS congress - Vimarsana News

Vicore IPF interim data selected as an oral "late-breaker" at the ERS congress

("Vicore"), a clinical-stage pharmaceutical company developing medicines targeting the angiotensin II type 2...

Trevi Therapeutics to Present at Upcoming August Conferences - Vimarsana News

Trevi Therapeutics to Present at Upcoming August Conferences

/PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (oral...

PureTech Reports Results from Phase 2 Study of LYT-100-COV in Post-Acute "Long" COVID with Respiratory Complications - Vimarsana News

PureTech Reports Results from Phase 2 Study of LYT-100-COV in Post-Acute "Long" COVID with Respiratory Complications

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced results from a Phase 2 study of LYT-100-COV (deupirfenidone) in ...